Avadel Pharmaceuticals plc (AVDL)
USD 7.73
(0.65%)
USD 7.73
(0.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.21 Million USD | -92.61% |
| 2022 | 57.04 Million USD | -39.51% |
| 2021 | 94.29 Million USD | 60.36% |
| 2020 | 58.8 Million USD | -48.81% |
| 2019 | 114.87 Million USD | 7.85% |
| 2018 | 106.51 Million USD | 753.59% |
| 2017 | -16.29 Million USD | 57.56% |
| 2016 | -38.4 Million USD | 39.95% |
| 2015 | -63.94 Million USD | -181.23% |
| 2014 | 78.72 Million USD | -0.44% |
| 2013 | 79.06 Million USD | 131.57% |
| 2012 | 34.14 Million USD | 5524.88% |
| 2011 | 607 Thousand USD | 114.7% |
| 2010 | -4.12 Million USD | 14.2% |
| 2009 | -4.81 Million USD | 79.87% |
| 2008 | -23.9 Million USD | -4.43% |
| 2007 | -22.88 Million USD | 52.65% |
| 2006 | -48.34 Million USD | -1843.24% |
| 2005 | 2.77 Million USD | 266.95% |
| 2004 | -1.66 Million USD | 98.45% |
| 2003 | -107.42 Million USD | -790.38% |
| 2002 | -12.06 Million USD | -233.93% |
| 2001 | -3.61 Million USD | 54.36% |
| 2000 | -7.91 Million USD | -207.81% |
| 1999 | -2.57 Million USD | 35.02% |
| 1998 | -3.95 Million USD | -889.5% |
| 1997 | -400 Thousand USD | 97.01% |
| 1996 | -13.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 941 Thousand USD | -77.69% |
| 2024 Q2 | 8.82 Million USD | 837.3% |
| 2023 Q4 | 4.21 Million USD | 115.18% |
| 2023 Q1 | 31.77 Million USD | -44.3% |
| 2023 Q3 | -27.78 Million USD | 0.29% |
| 2023 FY | 4.21 Million USD | -92.61% |
| 2023 Q2 | -27.86 Million USD | -187.69% |
| 2022 Q4 | 57.04 Million USD | -26.45% |
| 2022 FY | 57.04 Million USD | -39.51% |
| 2022 Q1 | 84.25 Million USD | -10.65% |
| 2022 Q2 | 82.38 Million USD | -2.22% |
| 2022 Q3 | 77.55 Million USD | -5.86% |
| 2021 Q3 | 85.88 Million USD | 11.95% |
| 2021 Q4 | 94.29 Million USD | 9.8% |
| 2021 Q1 | 84.49 Million USD | 43.69% |
| 2021 FY | 94.29 Million USD | 60.36% |
| 2021 Q2 | 76.71 Million USD | -9.2% |
| 2020 FY | 58.8 Million USD | -48.81% |
| 2020 Q1 | 52.56 Million USD | -54.25% |
| 2020 Q2 | 25.35 Million USD | -51.76% |
| 2020 Q3 | 45.89 Million USD | 81.03% |
| 2020 Q4 | 58.8 Million USD | 28.11% |
| 2019 Q3 | 111.76 Million USD | 5.2% |
| 2019 Q1 | 112.52 Million USD | 5.64% |
| 2019 FY | 114.87 Million USD | 7.85% |
| 2019 Q4 | 114.87 Million USD | 2.79% |
| 2019 Q2 | 106.24 Million USD | -5.58% |
| 2018 Q2 | 100.66 Million USD | 41.93% |
| 2018 Q1 | 70.92 Million USD | 535.22% |
| 2018 Q4 | 106.51 Million USD | 10.2% |
| 2018 Q3 | 96.65 Million USD | -3.99% |
| 2018 FY | 106.51 Million USD | 753.59% |
| 2017 Q2 | -42.62 Million USD | -35.7% |
| 2017 Q4 | -16.29 Million USD | 55.39% |
| 2017 FY | -16.29 Million USD | 57.56% |
| 2017 Q1 | -31.4 Million USD | 18.21% |
| 2017 Q3 | -36.53 Million USD | 14.28% |
| 2016 Q3 | -17.76 Million USD | 22.2% |
| 2016 Q4 | -38.4 Million USD | -116.22% |
| 2016 Q2 | -22.82 Million USD | 37.81% |
| 2016 FY | -38.4 Million USD | 39.95% |
| 2016 Q1 | -36.7 Million USD | 42.6% |
| 2015 FY | -63.94 Million USD | -181.23% |
| 2015 Q1 | 84.65 Million USD | 7.53% |
| 2015 Q2 | 94.44 Million USD | 11.57% |
| 2015 Q4 | -63.94 Million USD | 0.0% |
| 2014 Q3 | 71.94 Million USD | 114.82% |
| 2014 Q4 | 78.72 Million USD | 9.42% |
| 2014 Q2 | 33.49 Million USD | 73.38% |
| 2014 FY | 78.72 Million USD | -0.44% |
| 2014 Q1 | 19.31 Million USD | -75.57% |
| 2013 Q1 | 40.24 Million USD | 17.87% |
| 2013 Q2 | 76.65 Million USD | 90.46% |
| 2013 Q3 | 78.16 Million USD | 1.97% |
| 2013 Q4 | 79.06 Million USD | 1.16% |
| 2013 FY | 79.06 Million USD | 131.57% |
| 2012 Q4 | 34.14 Million USD | 0.0% |
| 2012 Q2 | 45.34 Million USD | -1.06% |
| 2012 FY | 34.14 Million USD | 5524.88% |
| 2012 Q1 | 45.83 Million USD | 7451.07% |
| 2011 FY | 607 Thousand USD | 114.7% |
| 2011 Q1 | -1.37 Million USD | 66.67% |
| 2011 Q2 | -7.42 Million USD | -439.83% |
| 2011 Q3 | -2.53 Million USD | 65.89% |
| 2011 Q4 | 607 Thousand USD | 123.95% |
| 2010 Q1 | 2.65 Million USD | 155.1% |
| 2010 FY | -4.12 Million USD | 14.2% |
| 2010 Q4 | -4.12 Million USD | -3957.94% |
| 2010 Q3 | 107 Thousand USD | 118.37% |
| 2010 Q2 | 49 Thousand USD | -98.15% |
| 2009 Q3 | -1.57 Million USD | 61.67% |
| 2009 Q4 | -4.81 Million USD | -206.43% |
| 2009 FY | -4.81 Million USD | 79.87% |
| 2009 Q1 | -14.91 Million USD | 37.59% |
| 2009 Q2 | -4.09 Million USD | 72.55% |
| 2008 Q3 | -25.16 Million USD | -31.9% |
| 2008 FY | -23.9 Million USD | -4.43% |
| 2008 Q1 | -28.03 Million USD | -22.5% |
| 2008 Q2 | -19.07 Million USD | 31.96% |
| 2008 Q4 | -23.9 Million USD | 5.01% |
| 2007 FY | -22.88 Million USD | 52.65% |
| 2007 Q4 | -22.88 Million USD | 12.38% |
| 2007 Q3 | -26.12 Million USD | 21.93% |
| 2007 Q2 | -33.46 Million USD | 18.45% |
| 2007 Q1 | -41.03 Million USD | 15.12% |
| 2006 Q3 | 2.88 Million USD | 245.61% |
| 2006 Q4 | -48.34 Million USD | -1774.98% |
| 2006 Q2 | -1.98 Million USD | -298.4% |
| 2006 Q1 | 999 Thousand USD | -63.97% |
| 2006 FY | -48.34 Million USD | -1843.24% |
| 2005 Q2 | 1.89 Million USD | 6.33% |
| 2005 FY | 2.77 Million USD | 266.95% |
| 2005 Q4 | 2.77 Million USD | -2.97% |
| 2005 Q3 | 2.85 Million USD | 50.5% |
| 2005 Q1 | 1.78 Million USD | 207.53% |
| 2004 Q4 | -1.66 Million USD | 98.32% |
| 2004 Q3 | -98.62 Million USD | 0.0% |
| 2004 FY | -1.66 Million USD | 98.45% |
| 2004 Q1 | -103.34 Million USD | 3.8% |
| 2004 Q2 | -98.62 Million USD | 4.56% |
| 2003 FY | -107.42 Million USD | -790.38% |
| 2003 Q4 | -107.42 Million USD | -430.54% |
| 2003 Q2 | -9.76 Million USD | 21.7% |
| 2003 Q1 | -12.46 Million USD | -3.34% |
| 2003 Q3 | -20.24 Million USD | -107.4% |
| 2002 Q3 | -12.57 Million USD | 0.0% |
| 2002 FY | -12.06 Million USD | -233.93% |
| 2002 Q4 | -12.06 Million USD | 4.04% |
| 2001 Q4 | -3.61 Million USD | 0.0% |
| 2001 FY | -3.61 Million USD | 54.36% |
| 2000 Q4 | -7.91 Million USD | 0.0% |
| 2000 FY | -7.91 Million USD | -207.81% |
| 1999 Q4 | -2.57 Million USD | 0.0% |
| 1999 FY | -2.57 Million USD | 35.02% |
| 1998 Q4 | -3.95 Million USD | 0.0% |
| 1998 Q1 | -2.7 Million USD | -575.0% |
| 1998 FY | -3.95 Million USD | -889.5% |
| 1997 FY | -400 Thousand USD | 97.01% |
| 1997 Q4 | -400 Thousand USD | 0.0% |
| 1996 Q4 | -13.4 Million USD | 0.0% |
| 1996 FY | -13.4 Million USD | 0.0% |
| 1996 Q1 | 800 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 99.031% |
| Embecta Corp. | 1.31 Billion USD | 99.679% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 95.524% |
| Dynavax Technologies Corporation | 106.63 Million USD | 96.045% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 99.081% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 99.026% |
| PainReform Ltd. | -7.95 Million USD | 153.044% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 94.374% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 126.972% |
| SCYNEXIS, Inc. | -19.35 Million USD | 121.793% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 144.72% |
| Cosmos Health Inc. | 8.59 Million USD | 50.912% |
| Journey Medical Corporation | -9.7 Million USD | 143.434% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 126.972% |
| Safety Shot Inc | -2.28 Million USD | 284.602% |
| Alpha Teknova, Inc. | 1.97 Million USD | -113.627% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 103.223% |
| Bright Green Corporation | 1.84 Million USD | -128.97% |
| Procaps Group, S.A. | 242.93 Million USD | 98.264% |
| Theratechnologies Inc. | 24.87 Million USD | 83.045% |
| Harrow Health, Inc. | 116.41 Million USD | 96.378% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 267.341% |
| Biofrontera Inc. | 4.05 Million USD | -3.969% |
| DURECT Corporation | -7.65 Million USD | 155.095% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 112.578% |
| Cronos Group Inc. | -663.32 Million USD | 100.636% |
| OptiNose, Inc. | 58.06 Million USD | 92.737% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 99.324% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 128.939% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 181.315% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 71.911% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 166.309% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -3846.322% |
| Radius Health, Inc. | 359.28 Million USD | 98.826% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -2038.341% |
| ProPhase Labs, Inc. | 19.23 Million USD | 78.072% |
| Phibro Animal Health Corporation | 454.84 Million USD | 99.073% |
| Procaps Group S.A. | 242.93 Million USD | 98.264% |
| Alvotech | 1.06 Billion USD | 99.604% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -14.655% |
| Viatris Inc. | 17.13 Billion USD | 99.975% |
| Rockwell Medical, Inc. | 4.45 Million USD | 5.364% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 186.467% |
| SIGA Technologies, Inc. | -148.68 Million USD | 102.836% |
| Tilray Brands, Inc. | 158.97 Million USD | 97.347% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 96.541% |
| Shineco, Inc. | 29.29 Million USD | 85.603% |
| PetIQ, Inc. | 351.93 Million USD | 98.802% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 245.342% |
| Incannex Healthcare Limited | -5.48 Million USD | 176.882% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 97.622% |
| Alimera Sciences, Inc. | 55.3 Million USD | 92.376% |
| Silver Spike Investment Corp. | -32.61 Million USD | 112.931% |
| Assertio Holdings, Inc. | -32.52 Million USD | 112.964% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 383.263% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 183.334% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 187.599% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 151.342% |
| Hempacco Co., Inc. | 13.61 Million USD | 69.026% |
| Talphera, Inc. | -5.72 Million USD | 173.711% |
| Alvotech | 1.06 Billion USD | 99.604% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 40.98% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 104.36% |
| Currenc Group, Inc. | -16.57 Million USD | 125.445% |
| Kamada Ltd. | -46.43 Million USD | 109.082% |
| Indivior PLC | -33.95 Million USD | 112.42% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -1518.35% |
| Flora Growth Corp. | -713 Thousand USD | 691.445% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 151.342% |
| Evolus, Inc. | 63.7 Million USD | 93.381% |
| HUTCHMED (China) Limited | -197.45 Million USD | 102.136% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 99.12% |
| Akanda Corp. | 3.9 Million USD | -7.992% |